Gerspach J - Search Results

1

Tumor necrosis factor-receptor 2 is up-regulated on lamina propria T cells in Crohn's disease and promotes experimental colitis in vivo.

Holtmann MH, Douni E, Schütz M, Zeller G, Mudter J, Lehr HA, Gerspach J, Scheurich P, Galle PR, Kollias G, Neurath MF. Holtmann MH, et al. Among authors: gerspach j. Eur J Immunol. 2002 Nov;32(11):3142-51. doi: 10.1002/1521-4141(200211)32:11<3142::AID-IMMU3142>3.0.CO;2-4. Eur J Immunol. 2002. PMID: 12555659 Free article.

2

Detection of membrane-bound tumor necrosis factor (TNF): an analysis of TNF-specific reagents.

Gerspach J, Götz A, Zimmermann G, Kolle C, Böttinger H, Grell M. Gerspach J, et al. Microsc Res Tech. 2000 Aug 1;50(3):243-50. doi: 10.1002/1097-0029(20000801)50:3<243::AID-JEMT8>3.0.CO;2-B. Microsc Res Tech. 2000. PMID: 10891890

3

Regulation of the murine NMDA-receptor-subunit NR2C promoter by Sp1 and fushi tarazu factor1 (FTZ-F1) homologues.

Pieri I, Klein M, Bayertz C, Gerspach J, van der Ploeg A, Pfizenmaier K, Eisel U. Pieri I, et al. Among authors: gerspach j. Eur J Neurosci. 1999 Jun;11(6):2083-92. doi: 10.1046/j.1460-9568.1999.00629.x. Eur J Neurosci. 1999. PMID: 10336677

4

Restoration of membrane TNF-like activity by cell surface targeting and matrix metalloproteinase-mediated processing of a TNF prodrug.

Gerspach J, Müller D, Münkel S, Selchow O, Nemeth J, Noack M, Petrul H, Menrad A, Wajant H, Pfizenmaier K. Gerspach J, et al. Cell Death Differ. 2006 Feb;13(2):273-84. doi: 10.1038/sj.cdd.4401735. Cell Death Differ. 2006. PMID: 16052236

5

Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins.

Schneider B, Münkel S, Krippner-Heidenreich A, Grunwald I, Wels WS, Wajant H, Pfizenmaier K, Gerspach J. Schneider B, et al. Among authors: gerspach j. Cell Death Dis. 2010 Aug 26;1(8):e68. doi: 10.1038/cddis.2010.45. Cell Death Dis. 2010. PMID: 21364672 Free PMC article.

6

A CD40-CD95L fusion protein interferes with CD40L-induced prosurvival signaling and allows membrane CD40L-restricted activation of CD95.

Assohou-Luty C, Gerspach J, Siegmund D, Müller N, Huard B, Tiegs G, Pfizenmaier K, Wajant H. Assohou-Luty C, et al. Among authors: gerspach j. J Mol Med (Berl). 2006 Sep;84(9):785-97. doi: 10.1007/s00109-006-0073-1. Epub 2006 Aug 4. J Mol Med (Berl). 2006. PMID: 16924474

7

Activation of CD95L fusion protein prodrugs by tumor-associated proteases.

Watermann I, Gerspach J, Lehne M, Seufert J, Schneider B, Pfizenmaier K, Wajant H. Watermann I, et al. Among authors: gerspach j. Cell Death Differ. 2007 Apr;14(4):765-74. doi: 10.1038/sj.cdd.4402051. Epub 2006 Oct 20. Cell Death Differ. 2007. PMID: 17053806

8

Therapeutic targeting of CD95 and the TRAIL death receptors.

Gerspach J, Pfizenmaier K, Wajant H. Gerspach J, et al. Recent Pat Anticancer Drug Discov. 2011 Sep;6(3):294-310. doi: 10.2174/157489211796957739. Recent Pat Anticancer Drug Discov. 2011. PMID: 21762072 Review.

9

Engineering death receptor ligands for cancer therapy.

Wajant H, Gerspach J, Pfizenmaier K. Wajant H, et al. Among authors: gerspach j. Cancer Lett. 2013 May 28;332(2):163-74. doi: 10.1016/j.canlet.2010.12.019. Epub 2011 Jan 14. Cancer Lett. 2013. PMID: 21236560 Review.

10

Genetic engineering of death ligands for improvement of therapeutic activity.

Gerspach J, Schneider B, Müller N, Otz T, Wajant H, Pfizenmaier K. Gerspach J, et al. Adv Exp Med Biol. 2011;691:507-19. doi: 10.1007/978-1-4419-6612-4_53. Adv Exp Med Biol. 2011. PMID: 21153356 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

24 results

Search Page

Filters